Clinical studies demonstrate comparable safety data for MIAVR and FS

Video

Clinical results have demonstrated comparable safety data for MIS and FS1,2,3

Check out the following clinical evidences (meta-analysis) 
Responsive image

Mortality Learn more ....

  • MIAVR is also related to an increase in long-term survival in comparison to FS1
  • In a recent study of 954 propensity-matched patients, in-hospital mortality was 0.4% with MIAVR compared to 2.3% with FS (p=0.013)1
expand

Long-term survival1

Responsive image
Responsive image

Blood loss Learn more ....

  • A meta-analysis involving 4,586 patients showed an average of 79 mL less blood loss with MIS compared with FS3
  • One study showed transfusions were needed in:4
0
0
Responsive image

Subscribe to our MIAVR Deep-Dive Newsletter (3 news for 3 months)

Visit Edwards Masters – our professional education website

See previous chapter

What are the different techniques in MIAVR, and what are the limitations?

See next chapter

MIAVR provides benefits to patients and surgeons

References 

AVR, Aortic Valve Replacement; FS, Full Sternotomy; MIS, Minimally Invasive Surgery; MIAVR, Minimally Invasive Aortic Valve Replacement; RDAVR, Rapid Deployment* Aortic Valve Replacement

* Simplified implantation through reduced suture steps

  1. Merk DR et al. Eur J Cardiothorac Surg. 2015:47:11–17.
  2. Ghanta RK et al. J Thorac Cardiovasc Surg. 2015;149:1060–1065.
  3. Brown ML et al. J Thorac Cardiovasc Surg. 2009;137:670–679.
  4. Neely RC et al. Ann Cardio thorac Surg. 2015;4(1):38–48.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All the other trademarks are the property of their respective owners. 

© 2018 Edwards Lifesciences Corporation. All rights reserved. E6713/03-18/HVT

Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com/eu

Subscribe here